Avantor vs IQVIA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Avantor Inc (AVTR)

Q3 202613 Jul – 18 Sep 2026

▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.
The guidance raise and beat are the core new event that changed the growth story.
Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.
Order growth and book-to-bill are the forward-looking evidence behind the recovery.
APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.
A concrete new market expansion that supports future demand.
Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.
The main counterweight: profits are still squeezed even as revenue stabilizes.

August 202613 Jul – 18 Sep 2026

▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.
The guidance raise and beat are the core new event that changed the growth story.
Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.
Order growth and book-to-bill are the forward-looking evidence behind the recovery.
APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.
A concrete new market expansion that supports future demand.
Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.
The main counterweight: profits are still squeezed even as revenue stabilizes.

Latest13 Jul – 18 Sep 2026

▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.
The guidance raise and beat are the core new event that changed the growth story.
Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.
Order growth and book-to-bill are the forward-looking evidence behind the recovery.
APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.
A concrete new market expansion that supports future demand.
Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.
The main counterweight: profits are still squeezed even as revenue stabilizes.

IQVIA Holdings Inc (IQV)

Q3 202614 Jul – 7 Oct 2026

▲3▼1

IQVIA Surges on Strong Q2, AI Push, and Buybacks

Q2 Beat and Guidance Raise IQVIA beat Q2 2026 estimates with revenue up 8.7% and EPS of $3.15, raised full-year guidance, and posted record bookings of $3.15B (up 19%) plus a $34.2B backlog. Shares jumped.
This is the primary new event that drove the stock higher during the period.
AI Platforms and Gene Therapy Partnership New AI platforms aim to cut trial delays by up to two years, and a Medera partnership expands gene therapy reach. These initiatives position IQVIA for future growth and efficiency.
These new strategic moves support the bullish narrative and future earnings potential.
Buybacks and Attractive Valuation The company executed $950M in buybacks, and the stock remains cheap at 16.2x forward earnings. Shares have rallied 42% in three months, aided by these repurchases.
Buybacks and low valuation attracted investors and contributed to the price rally.
Debt Refinancing Raises Interest Costs IQVIA priced $2B in 6.375% senior notes to refinance 5% debt, adding roughly $27.5M in annual interest expense—a modest but real headwind to future profits. Also, the rally means shares are no longer inexpensive.
This is a counterweight that could pressure future earnings and limit further upside.

August 202614 Jul – 7 Oct 2026

▲3▼1

IQVIA Surges on Strong Q2, AI Push, and Buybacks

Q2 Beat and Guidance Raise IQVIA beat Q2 2026 estimates with revenue up 8.7% and EPS of $3.15, raised full-year guidance, and posted record bookings of $3.15B (up 19%) plus a $34.2B backlog. Shares jumped.
This is the primary new event that drove the stock higher during the period.
AI Platforms and Gene Therapy Partnership New AI platforms aim to cut trial delays by up to two years, and a Medera partnership expands gene therapy reach. These initiatives position IQVIA for future growth and efficiency.
These new strategic moves support the bullish narrative and future earnings potential.
Buybacks and Attractive Valuation The company executed $950M in buybacks, and the stock remains cheap at 16.2x forward earnings. Shares have rallied 42% in three months, aided by these repurchases.
Buybacks and low valuation attracted investors and contributed to the price rally.
Debt Refinancing Raises Interest Costs IQVIA priced $2B in 6.375% senior notes to refinance 5% debt, adding roughly $27.5M in annual interest expense—a modest but real headwind to future profits. Also, the rally means shares are no longer inexpensive.
This is a counterweight that could pressure future earnings and limit further upside.

Latest14 Jul – 7 Oct 2026

▲3▼1

IQVIA's record bookings, AI launches, and cheap valuation drive the stock

Record bookings and raised guidance IQVIA's second-quarter results beat expectations, with adjusted earnings up 12.1% and revenue up 8.7%. Crucially, new clinical bookings jumped 19% to $3.2 billion, a record, and the company raised its full-year revenue outlook. Strong bookings signal future growth, which supports a higher stock price.
This is the core fundamental driver: accelerating demand and raised guidance directly boost investor confidence and the stock's value.
AI products speed up clinical trials IQVIA launched two AI-powered platforms: Predictive Clinical Development and Life Science Models. These tools aim to cut trial delays by up to two years and improve prediction accuracy. If adopted, they could win more business and make IQVIA's services more valuable, pushing the stock up over time.
New AI products are a key growth catalyst, showing innovation that can expand IQVIA's market and margins.
Cheap valuation and buybacks IQVIA trades at a forward P/E of 16.2, much lower than peers like Penumbra, and has a Value grade of B. The company also bought back $398 million of shares in Q2, reducing the share count. A low valuation plus buybacks can attract investors and lift the stock.
Valuation and capital returns are direct price drivers, making IQVIA look attractive relative to peers.
Higher interest costs from new debt IQVIA priced $2 billion in senior notes at 6.375% to refinance older 5% debt. This raises annual interest expense by about $27.5 million, slightly reducing future profits. While manageable, it's a headwind that could weigh on the stock.
This is the main counterweight: increased debt costs pressure earnings, balancing the positive drivers.

28 Jul – 12 Aug 2026

▲4

IQVIA beats Q2, raises 2026 outlook on record bookings

Q2 beat and raised 2026 guidance IQVIA reported Q2 revenue of $4.37 billion (up 8.7%) and earnings of $3.15 per share, beating estimates. Management raised full-year 2026 revenue and profit guidance, pushing shares up 5% after hours and nearly 14% the next day. This directly lifts the stock because future profits are now expected to be higher.
The earnings beat and guidance raise are the core new event that moved the stock this period.
Record $3.15B bookings and $34.2B backlog IQVIA's R&D Solutions unit signed a record $3.15 billion in new contracts in Q2, up 19% from a year ago. Its total contracted backlog hit a record $34.2 billion, with $9.2 billion expected to convert to revenue within 12 months. This signals strong future demand and supports the stock.
Record bookings and backlog are new, concrete evidence of future revenue growth that investors care about.
Medera collaboration expands gene therapy reach IQVIA announced a partnership with Medera to combine its clinical trial and commercialization network with Medera's cardiac gene therapy and human-based drug discovery platforms. This expands IQVIA's presence in cell and gene therapy, a high-growth area, and supports its long-term R&D pipeline.
This is a new strategic partnership that broadens IQVIA's technology and service offerings.
Stock up 42% in three months on strong results IQVIA shares have rallied 41.5% over the past three months, far outpacing the industry and the S&P 500. The run reflects the strong bookings, raised guidance, and $950 million of share buybacks in the first half of 2026. Momentum can attract more buyers, but also means the stock is no longer cheap.
This summarizes the market's reaction to the new fundamentals and highlights the strong momentum, while noting valuation risk.